Tags

Type your tag names separated by a space and hit enter

Clinical value of serum TAG-72 as a tumor marker for pancreatic carcinoma. Comparison with CA 19-9.
Int J Pancreatol. 1994 Jun; 15(3):171-7.IJ

Abstract

We evaluated the sensitivity and specificity of the carbohydrate antigen TAG-72 as a tumor marker for pancreatic cancer compared with the serum values of CA 19-9. Forty healthy controls, 58 patients with pancreatic carcinoma, and 45 patients with chronic pancreatitis were studied. In patients with pancreatic cancer, 47/58 (81%) and 26/58 (45%) had raised serum levels of CA 19-9 and TAG-72, respectively; the sensitivity of the tests was not influenced by jaundice. In the chronic pancreatitis patients, both CA 19-9 and TAG-72 were elevated in 2/45 patients (4.4%). Both tests showed a specificity of 95%. Consequently, the sensitivity of TAG-72 was too low compared with CA 19-9. Moreover, serum TAG-72 could not detect small pancreatic cancers. High levels of both tumor markers were found in advanced stages of cancer. No advantage was found using both CA 19-9 and TAG-72 for improving the detection of pancreatic cancer. TAG-72 serum levels > 10 U/mL are closely related to unresectability of the tumor. Only 4/17 (23%) of patients with resectable tumor had high TAG-72 levels. Serum TAG-72 expression seems to be more frequent in poorly-differentiated tumors than in well-differentiated cancers (56 vs 30% positivity rate).

Authors+Show Affiliations

Institute of Semeiotica Chirurgica, University of Padua, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

7930777

Citation

Pasquali, C, et al. "Clinical Value of Serum TAG-72 as a Tumor Marker for Pancreatic Carcinoma. Comparison With CA 19-9." International Journal of Pancreatology : Official Journal of the International Association of Pancreatology, vol. 15, no. 3, 1994, pp. 171-7.
Pasquali C, Sperti C, D'Andrea AA, et al. Clinical value of serum TAG-72 as a tumor marker for pancreatic carcinoma. Comparison with CA 19-9. Int J Pancreatol. 1994;15(3):171-7.
Pasquali, C., Sperti, C., D'Andrea, A. A., Costantino, V., Filipponi, C., & Pedrazzoli, S. (1994). Clinical value of serum TAG-72 as a tumor marker for pancreatic carcinoma. Comparison with CA 19-9. International Journal of Pancreatology : Official Journal of the International Association of Pancreatology, 15(3), 171-7.
Pasquali C, et al. Clinical Value of Serum TAG-72 as a Tumor Marker for Pancreatic Carcinoma. Comparison With CA 19-9. Int J Pancreatol. 1994;15(3):171-7. PubMed PMID: 7930777.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical value of serum TAG-72 as a tumor marker for pancreatic carcinoma. Comparison with CA 19-9. AU - Pasquali,C, AU - Sperti,C, AU - D'Andrea,A A, AU - Costantino,V, AU - Filipponi,C, AU - Pedrazzoli,S, PY - 1994/6/1/pubmed PY - 1994/6/1/medline PY - 1994/6/1/entrez SP - 171 EP - 7 JF - International journal of pancreatology : official journal of the International Association of Pancreatology JO - Int J Pancreatol VL - 15 IS - 3 N2 - We evaluated the sensitivity and specificity of the carbohydrate antigen TAG-72 as a tumor marker for pancreatic cancer compared with the serum values of CA 19-9. Forty healthy controls, 58 patients with pancreatic carcinoma, and 45 patients with chronic pancreatitis were studied. In patients with pancreatic cancer, 47/58 (81%) and 26/58 (45%) had raised serum levels of CA 19-9 and TAG-72, respectively; the sensitivity of the tests was not influenced by jaundice. In the chronic pancreatitis patients, both CA 19-9 and TAG-72 were elevated in 2/45 patients (4.4%). Both tests showed a specificity of 95%. Consequently, the sensitivity of TAG-72 was too low compared with CA 19-9. Moreover, serum TAG-72 could not detect small pancreatic cancers. High levels of both tumor markers were found in advanced stages of cancer. No advantage was found using both CA 19-9 and TAG-72 for improving the detection of pancreatic cancer. TAG-72 serum levels > 10 U/mL are closely related to unresectability of the tumor. Only 4/17 (23%) of patients with resectable tumor had high TAG-72 levels. Serum TAG-72 expression seems to be more frequent in poorly-differentiated tumors than in well-differentiated cancers (56 vs 30% positivity rate). SN - 0169-4197 UR - https://www.unboundmedicine.com/medline/citation/7930777/Clinical_value_of_serum_TAG_72_as_a_tumor_marker_for_pancreatic_carcinoma__Comparison_with_CA_19_9_ L2 - https://medlineplus.gov/pancreatitis.html DB - PRIME DP - Unbound Medicine ER -